Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026

Alnylam Pharmaceuticals, Inc. (ALNY)

A forensic read on Alnylam Pharmaceuticals, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

C · Mixed — selective

Forensic grade

Safe

Financial health

7.0

Distress distance

Clean

Earnings quality

Forensic signals

35.2

P / E (ttm)

39.8%

ROE

$29.0B

Market cap

65.2%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Alnylam Pharmaceuticals, Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 7.0, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+3.4%/yr

FY2022–FY2025

Share-count dilution. Diluted share count changed +11% over the last 3 years to FY2025 (+3.4%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~3.4% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~10%.

9% of rev

FY2025

Stock-based comp load. Stock-based compensation ran 9% of revenue and 75% of free cash flow in FY2025 — about $2.59 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 3.5% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.

Key fundamentals

Latest Revenue$3.71B

Revenue Growth YoY+65.2%

Revenue CAGR (3yr)+53.0%

Net Margin8.4%

Free Cash Flow$465.4M

Return on Equity39.8%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Alnylam Pharmaceuticals, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.